The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
Recruiting · Not applicable · NCT05446272
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
At a glance
- Research payments reported, 2025
- $5,600
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 478
About the trial
- Sponsor
- University of Pennsylvania (with National Heart, Lung, and Blood Institute (NHLBI))
- Tested
- NIV-NAVA (device), NS-NIPPV (device)
- Dates
- Started 2022-08-03; completion 2027-12-31
- Results posted
- Not yet
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Maquet Critical Care Ab reported $5,600 in research payments for this study in 2025 (2 payments).
Products named: Base Unit Servo-U
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.